Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF FEBRUARY 07, 2026 SAM #8839
SOLICITATION NOTICE

65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Notice Date

2/5/2026 5:48:21 AM
 

Notice Type

Solicitation
 

NAICS

325412 — Pharmaceutical Preparation Manufacturing
 

Contracting Office

DEFENSE HEALTH AGENCY (DHA) JBSA FT SAM HOUSTON TX 78234 USA
 

ZIP Code

78234
 

Solicitation Number

HT9402-26-Q-9201
 

Response Due

4/2/2026 10:00:00 AM
 

Archive Date

10/02/2026
 

Point of Contact

Tracy Banks, Kirk Heyen
 

E-Mail Address

tracy.e.banks2.civ@health.mil, kirk.e.heyen.ctr@health.mil
(tracy.e.banks2.civ@health.mil, kirk.e.heyen.ctr@health.mil)
 

Small Business Set-Aside

NONE No Set aside used
 

Description

The Department of Defense (DoD) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P& T COMMITTEE MEETING: The following MAY 2026 drug classes/subclasses will be reviewed: a. Antihemophilic Agents - Non-Factor Agents ALHEMO PEN HEMLIBRA HYMPAVZI PEN QFITLIA b. Leukemia and Lymphoma - BCR-ABL-TKI BOSULIF DANZITEN ICLUSIG IMKELDI PHYRAGO SCEMBLIX SPRYCEL TASIGNA NILOTNIB TARTRATE The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9201. Pre-quotation teleconference is on February 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
 

Web Link

SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/832e20c89c0b4f549a4550a833b16cef/view)
 

Place of Performance

Address: San Antonio, TX 78230, USA

Zip Code: 78230

Country: USA
 

Record

SN07706086-F 20260207/260205230042 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |